Home / About us / Leadership / Meagan McKenna, MSc
Meagan McKenna, MSc
Senior Project Manager
Meagan holds a Bachelor of Science (Honors) in Neuroscience with a minor in Biology and Master of Science in Pharmacology from Dalhousie University. Her graduate research focused on the evaluation of anti-inflammatory and analgesic compounds in preclinical models of arthritis, providing a deep understanding of translational research and drug development.
She joined AGADA as a Research Associate, leading preclinical trials and participating in clinical site training and management. Meagan has further expanded her leadership and commercial expertise through Harvard Business School’s Leadership Principles certificate program and the LNS Sales Accelerator Program.
As Senior Project Manager, Meagan oversees AGADA’s complex client portfolios, providing strategic leadership from proposal development through project execution. She mentors the project management team, leads contract negotiations and pricing strategy, and ensures projects are delivered with scientific rigor, operational excellence, and financial accountability. By fostering strong client partnerships and driving continuous improvement initiatives, Meagan plays an integral role in advancing AGADA’s reputation as a trusted research partner while supporting the Company’s long-term growth and success.
Get in touch
To learn how AGADA Biosciences could support your program, get in touch with our team and start the conversation.
How we work
We bring an agile, collaborative and responsive approach to every engagement, shaping our support around the needs of your program rather than a rigid process. Whether you engage us at a single stage or across multiple points in development, we work to de-risk programs, protect data integrity and help your teams progress with confidence.
1
Refined for your program:
We shape our approach around the needs of each program, not the other way around.
2
Direct access to senior experts:
Our lean model keeps scientific expertise close to the work and communication clear.
3
Built to de-risk progress:
We help you de-risk development through rigorous science and practical support.
4
Protecting data integrity:
Our work is designed to support reliable outputs and maintain confidence in the data.
Why AGADA?
We bring dedicated expertise to programs where there is little room for error, providing the scientific support, responsiveness and program fit that help rare disease teams move forward with clarity.
Decade of specialization:
Founded in 2013 as a spinout from Children’s National Medical Center to provide specialist scientific support for rare disease drug development.
Consistent audit success:
We successfully pass an average of five sponsor audits annually to support clinical trials across multiple phases.
Historical benchmarking:
We leverage archival data from over 100 trials in mouse models of muscular dystrophy to accurately power your efficacy studies.
Dedicated scale:
We operate with a team of approximately 50 employees, entirely focused on executing complex rare disease programs.
Meet more of the leadership team
